

## **Diagnostic accuracy of Panbio™ rapid antigen tests on oropharyngeal swabs for detection of SARS-CoV-2**

Marie Thérèse Ngo Nsoga<sup>1#</sup>, Ilona Kronig<sup>1#</sup>, Francisco Javier Perez Rodriguez<sup>3</sup>,  
Pascale Sattouet-Roche<sup>3</sup>, Diogo Da Silva<sup>1</sup>, Javan Helbling<sup>1</sup>, Jillian A. Sacks<sup>4</sup>,  
Margaretha de Vos<sup>4</sup>, Erik Boehm<sup>1</sup>, Angèle Gayet-Ageron<sup>5</sup>, Alice Berger<sup>1</sup>, Frédérique  
Jacquieroz-Bausch<sup>7</sup>, François Chappuis<sup>7</sup>, Laurent Kaiser<sup>1,2,6</sup>, Manuel Schibler<sup>1,2,3</sup>,  
Adriana Renzoni<sup>2</sup>, Isabella Eckerle<sup>1,2,3,6</sup>

### **Authors and affiliations**

<sup>1</sup> Infectious Disease Division, Geneva University Hospitals, Geneva, Switzerland.

<sup>2</sup> Laboratory of Virology, Laboratory Medicine Division, Geneva University Hospitals, Geneva, Switzerland.

<sup>3</sup> Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland.

<sup>4</sup> Foundation for Innovative New Diagnostics, Geneva, Switzerland

<sup>5</sup> CRC & Division of Clinical-Epidemiology, Department of Health and Community Medicine, University of Geneva & University Hospitals of Geneva

<sup>6</sup> Department of Microbiology and Molecular Medicine, University of Geneva, Geneva, Switzerland

<sup>7</sup> Department of Primary Care, Geneva University Hospitals, Geneva, Switzerland

Keywords: oropharyngeal swab, SARS-CoV-2, antigen-detecting test, rapid test

**Corresponding Author:**

*\*Corresponding author.* Isabella Eckerle, Geneva Centre for Emerging Viral Diseases, Geneva University Hospitals, Geneva, Switzerland. Geneva University Hospitals, Rue Gabrielle-Perret-Gentil 4, 1205 Geneva 14, Switzerland. Tel: +41223729820; Email: Isabella.Eckerle@hcuge.ch

# contributed equally

## **Abstract**

### *Background*

Antigen-detecting rapid diagnostic tests (Ag-RDTs) for the detection of SARS-CoV-2 offer new opportunities for testing in the context of the COVID-19 pandemic. Nasopharyngeal swabs (NPS) are the reference sample type, but oropharyngeal swabs (OPS) may be a more acceptable sample type in some patients.

### *Methods*

We conducted a prospective study in a single screening center to assess the diagnostic performance of the Panbio™ COVID-19 Ag Rapid Test (Abbott) on OPS compared with reverse-transcription quantitative PCR (RT-qPCR) using NPS.

### *Results*

402 outpatients were enrolled in a COVID-19 screening center, of whom 168 (41.8%) had a positive RT-qPCR test. The oropharyngeal Ag-RDT sensitivity compared to nasopharyngeal RT-qPCR was 81% (95%CI: 74.2-86.6). Two false positives were noted out of the 234 RT-qPCR negative individuals, which resulted in a specificity of 99.1% (95%CI: 96.9-99.9) for the Ag-RDT.

For cycle threshold values  $\leq 26.7$  ( $\geq 1E6$  SARS-CoV-2 genomes copies/mL, a presumed cut-off for infectious virus), 96.3% sensitivity (95%CI: 90.7-99.0%) was obtained with the Ag-RDT using OPS.

### *Interpretation*

Based on our findings, the diagnostic performance of the Panbio™ Covid-19 RDT with OPS samples meet the criteria required by the WHO for Ag-RDTs (sensitivity  $\geq 80\%$  and specificity  $\geq 97\%$ ).

## Introduction

The SARS-CoV-2 pandemic has killed millions of people worldwide(1). Large scale testing allows for identification and isolation of infected individuals, and quarantining contacts, thus limiting community transmission. Currently, SARS-CoV-2 RT-qPCR performed on nasopharyngeal swabs (NPS) is the gold-standard diagnostic test. While displaying excellent sensitivity and specificity, RT-qPCR is costly, subject to reagent and material shortages during pandemics, and requires experienced personnel and complex infrastructure. Antigen rapid diagnostic tests (Ag-RDTs) are easy to use, more affordable, decentralizable, and provide quick results; offering an attractive alternative to RT-qPCR during pandemics. Their drawbacks are mainly reduced sensitivity relative to RT-qPCR.

The World Health Organization (WHO) considers a sensitivity  $\geq 80\%$  and a specificity  $\geq 97\%$  as acceptable performance for SARS-CoV-2 Ag-RDTs(2). Currently, only validations of Ag-RDTs performed with NPS have shown satisfactory results(3–12), and no studies have evaluated Ag-RDTs using oropharyngeal swabs (OPS). OPS sampling could be a useful alternative to NPS sampling, as seen with RT-qPCR tests(13,14). Here we describe a prospective study comparing the diagnostic performances of an Ag-RDT using OPS with RT-qPCR using NPS for detection of SARS-CoV-2.

## Methods

### *Ethics*

The study was approved by the cantonal ethics committee (Commission Cantonale d'Ethique de la Recherche, CCER, Geneva, Nr. 2020-02323). All enrolled patients provided written informed consent form.

### *Setting, study design and participants*

The study took place from November 3 to 19, 2020, at an outpatient SARS-CoV-2 screening site at the Geneva University Hospitals. The majority of patients had symptoms compatible with SARS-CoV-2 infection, and a small proportion were asymptomatic contacts. All participants were  $\geq 16$  years old.

### *Sampling procedure*

Participants were swabbed twice: one NPS performed by a nurse at the screening site, for the reference RT-qPCR; and an OPS done by an experienced doctor, using a tongue depressor in a well-lit environment with an emphasis on consistent technique, for the Ag-RDT.

A pilot study tested 28 RT-qPCR-positive individuals without ensuring the back of the oropharynx was reached, yielding only 11 Ag-RDT positives (Supplemental table 1). Therefore, patients were only included if the posterior wall of the oropharynx could be reached.

### *Data collection*

The clinical data collected for each patient was: duration of any symptoms when samples were collected, potential close contact with a positive person within 14 days,

symptoms (rhinorrhea, odynophagia, myalgia, chills, dry vs productive cough, hemoptysis, fever, anosmia, ageusia, gastrointestinal symptoms, asthenia, dyspnea, chest pain and headache), and comorbidities (hypertension, cardiovascular disease, chronic lung disease, diabetes, chronic renal failure, active cancer, severe immunosuppression, pregnancy and obesity (BMI > 40 kg/m<sup>2</sup>)).

#### *Ag-RDT procedure*

Aside from the sample type, the Panbio™ (Abbott) Ag-RDT device was run and read by a biologist according to the manufacturer's protocol. Equivocal results were read by a second healthcare worker.

#### *SARS-CoV-2 detection by RT-qPCR*

All NPS samples were analyzed using the Cobas® SARS-CoV-2 RT-PCR assay on the 6800 system (Roche), targeting ORF1 and the E-gene. Cycle-threshold (Ct) values for the E-gene were converted into viral load (VL) with the following formula:  $\log_{10} \text{ SARS-CoV-2 copies/mL} = (\text{Ct} - 44.5) / -3.3372$ .

#### *Statistical methods*

Ag-RDT sensitivity and specificity was determined relative to RT-PCR. With a positivity rate of 37.5%, and an Ag-RDT sensitivity/specificity of 85%/95%, a sample size of 400 could determine sensitivity and specificity with confidence intervals (CI) of 79.3-90.7% and 92.3-97.7%, respectively. Fischer's exact test was used to compare Ag-RDT sensitivity by Ct values (above/below 26.7). All analyses were performed

using STATA version intercooled 16 (Stata Corp., College Station, TX, USA). Statistical significance was defined as  $p < 0.05$  (two-sided).

## Results

During the study period, 402 participants were included. Eight patients were excluded either because the throat was insufficiently accessible or because consent was withdrawn. The participants' socio-demographic characteristics are summarized in supplemental table 2. 168 participants (41.8%) were RT-qPCR-positive with a mean Ct value of 24.97 (SD  $\pm 5.63$ ,  $3.3E6$  SARS-CoV-2 copies/mL equivalent) for 166 RT-PCR analyses. Two specimens, positive for the ORF1 target at a high CT values but negative for the E-gene, were interpreted as positive in the analysis for sensitivity and specificity but excluded from Figure 1; both were Ag-RDT negative.

All RT-qPCR-positive participants were symptomatic. Compared to RT-qPCR, the sensitivity of the Ag-RDT was 81% (95%CI: 74.2-86.6). Two Ag-RDT false-positives were observed, thus the specificity was 99.1% (95%CI: 96.9-99.9) (**Table 1**).

The sensitivity of the test for Ct values  $\leq 26.7$  (equivalent to  $\geq 1E6$  SARS-CoV-2 copies/mL) was 96.3% (90.7-99.0%). Of the OPS samples from RT-PCR-positive individuals, mean Ct value for Ag-RDT-positive samples was 23.17 while the mean Ct value for Ag-RDT-negative samples was 32.82, equivalent to  $1.1E7$  and  $1.3E4$  SARS-CoV2 copies/mL, respectively (**Figure 1**).

Ag-RDTs have shown higher sensitivity in individuals with lower Ct values/higher VL, and in the first days post onset of symptoms (DPOS)(3). As false-negative Ag-RDT results correlate with low VLs, we expected higher numbers of false negative results in samples collected later after the onset of symptoms.

For patients presenting within 0-4 DPOS, the sensitivity was 86.1% (n=101; 95%CI: 77.8-92.2). For those presenting within 5-7 and 8-11 DPOS, it was 73.7% (n=19; 95%CI: 48.8-90.9) and 70.6% (n=17; 95%CI: 44.0-89.7), respectively.

Sensitivities in the presence of fever or chills; fever and cough; fever and anosmia or fever and cough; and non-specific symptoms, were: 87.5% (n=80; 95%CI: 78.2-93.8), 92.3% (n=39; 95%CI: 79.1-98.4), 92.5% (n=53; 95%CI: 81.8-97.9), and 84.0% (n=25; 95%CI: 63.9-95.5), respectively.

## Discussion

There are over 10 clinical studies (8 preprints, 2 published) evaluating the performance of the Panbio™ Ag-RDT(3–12) using only manufacturer recommended NPS. Those studies, with over 6000 subjects, have reported sensitivity and specificity ranges of 71.4%-91.7% and 94.9%-100%, respectively. Considering only Ct values <30 yielded test sensitivities from 87.7% to 97.8%(3,6–9). Similarly, samples from <5 DPOS yielded a sensitivity between 77.2 and 94.8%(3,5,6,8,9).

For some patients in whom NPS sampling is not feasible, OPS could be an attractive alternative, thus OPS sample validation is critical. This is the first publication investigating the diagnostic accuracy of the Panbio™ Ag-RDT using OPS. Our results meet show this off-label use to still meets the WHO targets of ≥80% sensitivity and ≥97% specificity(2). Interestingly, while ensuring high OPS sample quality, we obtained similar results to our previously published NPS evaluation, with no statistical difference in sensitivity and specificity(3).

We previously demonstrated similar clinical and analytical sensitivities between NPS and OPS sampling for SARS-CoV-2 detection using RT-qPCR(14). However, some studies showed reduced(13) sensitivity and lower rates of virus isolation in cell



culture for OPS when compared to NPS, suggesting a risk of reduced Ag-RDT sensitivity when using OPS(15).

Our present study shows that despite the use of OPS, contrary to manufacturer recommendations, we obtained highly reliable results. Similar to studies on NPS specimens, the highest sensitivity was seen in the early symptomatic period as well as for patients presenting with high nasopharyngeal VL. Although a few positive samples with lower Ct values were missed, the majority of false-negative samples were from individuals with high Ct values ( $\geq 30$ ), corresponding to a low VL below the presumed cut-off for infectious virus ( $Ct \leq 26.7$  in our hands); these results suggest that these individuals are not likely to be contagious and that these false-negative Ag-RDT results should not result in further transmission.

In conclusion, the use of Ag-RDTs with OPS might prove to be an acceptable alternative to NPS, and could increase test acceptance for selected groups such as children.

### **Acknowledgements**

We thank all nurses and staff at the testing Centre Sectors of our institution as well as the patients for their willingness to participate in the study.

## **Funding**

This work was supported by Foundation of Innovative Diagnostics (FIND), by Private HUG Foundation and by Pictet Charitable Foundation.

Marie Thérèse Ngo Nsoga is a beneficiary of the excellence grant from the Swiss Confederation and the grant from the humanitarian commission of the University Hospital of Geneva.

## References:

1. WHO Coronavirus Disease (COVID-19) Dashboard [Internet]. [cited 2020 Nov 30]. Available from: <https://covid19.who.int>
2. COVID-19 Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.1.0 [Internet]. [cited 2020 Oct 8]. Available from: <https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1>
3. Berger A, Nsoga MTN, Perez-Rodriguez FJ, Aad YA, Sattonnet-Roche P, Gayet-Ageron A, et al. Diagnostic accuracy of two commercial SARS-CoV-2 Antigen-detecting rapid tests at the point of care in community-based testing centers. medRxiv. 2020 Nov 23;2020.11.20.20235341.
4. Fenollar F, Bouam A, Ballouche M, Fuster L, Prudent E, Colson P, et al. Evaluation of the Panbio Covid-19 rapid antigen detection test device for the screening of patients with Covid-19. J Clin Microbiol. 2020 Nov 2;JCM.02589-20.
5. Linares M, Pérez-Tanoira R, Carrero A, Romanyk J, Pérez-García F, Gómez-Herruz P, et al. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. Journal of Clinical Virology. 2020 Oct 16;104659.
6. Schwob JM, Miauton A, Petrovic D, Perdrix J, Senn N, Jatou K, et al. Antigen rapid tests, nasopharyngeal PCR and saliva PCR to detect SARS-CoV-2: a prospective comparative clinical trial. medRxiv. 2020 Nov 24;2020.11.23.20237057.
7. Gremmels H, Winkel BMF, Schuurman R, Rosingh A, Rigter NAM, Rodriguez O, et al. Real-life validation of the Panbio COVID-19 Antigen Rapid Test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection. medRxiv. 2020 Jan 1;2020.10.16.20214189.
8. Merino-Amador P, Guinea J, Muñoz-Gallego I, González-Donapetry P, Galán J-C, Antona N, et al. Multicenter evaluation of the Panbio™ COVID-19 Rapid Antigen-Detection Test for the diagnosis of SARS-CoV-2 infection. medRxiv. 2020 Nov 20;2020.11.18.20230375.
9. Bullete O, Lorente P, Leiva A, Carandell E, Oliver A, Rojo E, et al. Evaluation of the Panbio™ rapid antigen test for SARS-CoV-2 in primary health care centers and test sites. medRxiv. 2020 Nov 16;2020.11.13.20231316.
10. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, et al. Field evaluation of a rapid antigen test (Panbio™ COVID-19 Ag Rapid Test Device) for the diagnosis of COVID-19 in primary healthcare centers. medRxiv. 2020 Oct 20;2020.10.16.20213850.
11. Torres I, Poujois S, Albert E, Colomina J, Navarro D. Real-life evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for SARS-CoV-2

detection in asymptomatic close contacts of COVID-19 patients. medRxiv. 2020 Dec 2;2020.12.01.20241562.


12. Alemany A, Baro B, Ouchi D, Ubals M, Corbacho-Monné M, Vergara-Alert J, et al. Analytical and Clinical Performance of the Panbio COVID-19 Antigen-Detecting Rapid Diagnostic Test. medRxiv. 2020 Nov 3;2020.10.30.20223198.
13. Wang H, Liu Q, Hu J, Zhou M, Yu M, Li K, et al. Nasopharyngeal Swabs Are More Sensitive Than Oropharyngeal Swabs for COVID-19 Diagnosis and Monitoring the SARS-CoV-2 Load. *Front Med (Lausanne)* [Internet]. 2020 Jun 18 [cited 2020 Aug 31];7. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7314917/>
14. Calame A, Mazza L, Renzoni A, Kaiser L, Schibler M. Sensitivity of nasopharyngeal, oropharyngeal, and nasal wash specimens for SARS-CoV-2 detection in the setting of sampling device shortage. *Eur J Clin Microbiol Infect Dis*. 2020 Sep 17;1–5.
15. Vetter P, Eberhardt CS, Meyer B, Martinez Murillo PA, Torriani G, Pigny F, et al. Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series. Spiropoulou CF, editor. *mSphere*. 2020 Dec 23;5(6):e00827-20.

## Tables

**Table 1: Diagnostic performance of the Panbio™ rapid antigen test in oropharyngeal specimens**

	Reference RT-qPCR positive	Reference RT-qPCR Negative	Total
Panbio™ positive	136	2	138
Panbio™ negative	32	232	264
Total	168	234	402
Sensitivity	81% (95% CI = 74.2 - 86.6%)		
Specificity	99% (95% CI = 96.9% - 99.9%)		
Mean CT	24.97		
(±SD, median, range) (n=166)	(±5.63, 24.23-2-29)		

## Figures



**Figure 1. SARS-CoV-2 detection by Panbio™ antigen rapid test using OPS compared to the reference RT-qPCR detection method using NPS. A. Ct values, viral load and Ag-RDT results for 166 RT-PCR-positive individuals. Horizontal bars represent median and standard deviation. Dotted line: Ct value of 26.7 or 1E6 SARS-**

CoV-2 RNA copy numbers/mL. Note: Two samples were excluded because of low viral load (positive signal in ORF1 assay but negative signal in E-gene target, thus excluded from the graph. Both samples gave a negative RDT result). **B.** Ct values, viral load, days post symptom onset and Ag-RDT results for 139 patients for which information on day of symptom onset was available. Dotted line: Ct value of 26.7 or 1E6 SARS-CoV-2 RNA copy numbers/mL.

## Supplemental Tables and Figures

Supplemental Table 1: Results of the pilot study

	RT-qPCR positive	RT-qPCR negative	Total
Panbio™ positive	11	0	11
Panbio™ negative	17	28	45
Total	28	28	56
Sensitivity	39.28% (95% CI = 21.5 - 59.4%)		
Specificity	100% (95% CI = 87.7 - 100%)		

Supplemental Table 2. Patient

### Characteristics

Mean age ( $\pm$ SD, median, range)	39.9 ( $\pm$ 14.5, 38, 16-80)
Sex distribution, n (%)	
Women	224 (55.7)
Men	178 (44.3)
Mean days from symptom onset to PCR (SD, Median, range) (n=141)	4.1 ( $\pm$ 3.3, 3, 0-24)
Comorbidities among positive PCR, n (%)	38 (22.6)
Number of patients with symptoms, n (%)	168 (41.8)
Symptoms, n (%) (n=168) (descending order in frequencies)	
Asthenia	101 (60.1)
Headaches	99 (58.9)
Myalgia	81 (48.2)
Chills or fever	80 (47.6)
Dry or productive cough	73 (43.5)
Anosmia, agueusia	71 (42.3)
Odynophagia	68 (40.5)
Digestive signs	38 (22.6)
Dyspnea	7 (4.2)
Chest pain	4 (2.4)
Other	12 (7.1)
Had a contact with positive cases within last 14 days, n (%)	87 (51.8)

